Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Now That Telemedicine is a Mainstay in Cancer Care, One Expert Notes When Patients Should Opt for Virtual Appointments

April 6th 2022, 7:00pm

Article

The COVID-19 pandemic brought on a huge surge in the use of telemedicine for cancer care, but now as the pandemic is slowing down, an expert said that there are certain times when telemedicine will do, while other situations warrant an in-person visit with the doctor.

CAR-T Cell Therapies Offer ‘An Opportunity for Majority of Patients’ With Lymphoma to Be Treated

March 14th 2022, 3:00pm

Video

Unlike stem cell transplant, which has strict eligibility criteria, the majority of patients with blood cancer may be able to receive CAR-T cell therapy, regardless of other comorbidities, explained an expert.

CAR-T Cell Therapies Provide Patients With Mantle Cell and Follicular Lymphoma a ‘One and Done’ Treatment Option, Expert Says

March 2nd 2022, 10:00pm

Article

CAR-T cell therapies offer patients with lymphoma a chance for long-term remission, but none have yet to receive a greenlight from the FDA as a first line of treatment.

Addition of Ofatumumab to Aggressive Chemotherapy Regimen Yields High Response Rates in Newly Diagnosed Mantle Cell Lymphoma

March 2nd 2022, 2:00pm

Article

Treatment with ofatumumab plus an aggressive regimen of chemotherapies resulted in a response rate of more than 80% in patients with newly diagnosed mantle cell lymphoma.

Experimental Lymphoma Drug Shows ‘Robust Clinical Activity,’ Researchers Say

February 25th 2022, 2:00pm

Article

Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.

My Oncologist Gave Me a Pseudo-Medication Taper That Made Me Feel Like I Was Losing Control

February 16th 2022, 6:00pm

Article

In the midst of my treatment for mantle cell lymphoma, I had to suffer through the feeling of wanting to crawl out of my own skin when my oncologist gave me a medication tapering plan that was not gradual enough.

Decades of MCL Treatment Advancements a ‘Godsend’ for Patients

February 14th 2022, 8:00pm

Article

From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades.

Supportive Care and Palliative Care May Improve Outcomes in Patients Receiving CAR-T Cell Therapy

February 14th 2022, 4:00pm

Article

Supportive care should be implemented promptly after patients receive CAR-T cell therapy, but as one expert notes, patients with cancer are often referred for this care too late.

Clinical Trial Testing Effectiveness of LOXO-305 in Mantle Cell Lymphoma Now Open to Patients

February 9th 2022, 10:00pm

Article

A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.

Prophylactic Monoclonal Antibodies Recommended to Protect Certain Patients With Cancer From COVID-19

January 11th 2022, 8:30pm

Article

The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.

x